Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07474740 · ClinicalTrials.gov registry record · NA
Evaluating the Efficacy of Voice Therapy for Neurogenic Voice Disorders
A NA study of Speakers With Neurogenic Voice Disorders, sponsored by University of Texas at Austin.
- Active
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07474740: Active NA study of Speakers With Neurogenic Voice Disorders, sponsored by University of Texas at Austin.
NCT07474740 is a NA study of Speakers With Neurogenic Voice Disorders that is active but no longer recruiting, run by University of Texas at Austin. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07474740, a NA study of Speakers With Neurogenic Voice Disorders, is active but no longer recruiting, sponsored by University of Texas at Austin.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the efficacy of voice therapy for neurogenic voice disorders. The main questions are: Does voice therapy improve patient-reported quality of life in speakers with neurogenic voice disorders? Does voice therapy improve listener perception of voice in speakers with neurogenic voice disorders? Does voice therapy improve acoustical analyses of voice in speakers with neurogenic voice disorders? Does voice therapy improve physiologic function in speakers with neurogenic voice disorders?
Primary Outcome
Participants will be asked to rate their perception of the voice strategy on a 6-point Likert scale (0 = not at all, 5 = very much): 1) My voice was shaky when I used the strategy, 2) It was effortful to speak when I used the strategy, 3) It was difficult to use the strategy, 4), I liked the sound of my voice when I used the strategy.
Conditions Studied
Interventions
- BEHAVIORAL Breathy voice
Study Locations (1)
Texas
- The University of Texas at Austin - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2028-06-04 |
| Phase | NA |
What the registry record for NCT07474740 still lists
NCT07474740 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Speakers With Neurogenic Voice Disorders appearing as the primary indexed condition, and to 1 intervention - of which Breathy voice is the first listed.
NCT07474740 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07474740 about?
NCT07474740 is a clinical study titled "Evaluating the Efficacy of Voice Therapy for Neurogenic Voice Disorders". The goal of this study is to evaluate the efficacy of voice therapy for neurogenic voice disorders. The main questions are: Does voice therapy improve patient-reported quality of life in speakers with neurogenic voice disorders? Does voice therapy improve listener perception of voice in speakers wi...
What is the current status of trial NCT07474740?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-06-04. Estimated completion is 2028-06-04.
What conditions does trial NCT07474740 study?
This clinical trial studies the following conditions: Speakers With Neurogenic Voice Disorders.
What interventions are being tested in trial NCT07474740?
The interventions under investigation include: Breathy voice (BEHAVIORAL).
Who is sponsoring clinical trial NCT07474740?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07474740 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07474740's enrollment target sits among peer trials
40 1447th of 2000 higher than 465 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI